We are live on ! Find out more
II

Ishara Investments Portfolio holdings

AUM $136M
This Fund
S&P 500
This Quarter Est. Return
+1.21%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$106M
AUM Growth
+$18.2M
Cap. Flow
+$18.5M
Cap. Flow %
17.55%
Top 10 Hldgs %
50.89%
Holding
56
New
18
Increased
10
Reduced
9
Closed
19

Top Buys

Rank Stock Value
1
AXSM icon
Axsome Therapeutics
AXSM
+$7.08M
2
KALV
KalVista Pharmaceuticals
KALV
+$4.46M
3
VERA icon
Vera Therapeutics
VERA
+$3.53M
4
ARWR icon
Arrowhead Research
ARWR
+$3.5M
5
VSTM icon
Verastem
VSTM
+$3.39M

Top Sells

Rank Stock Value
1
PRAX icon
Praxis Precision Medicines
PRAX
+$5.4M
2
NUVB icon
Nuvation Bio
NUVB
+$3.58M
3
ANNX icon
Annexon
ANNX
+$3.24M
4
BBIO icon
BridgeBio Pharma
BBIO
+$2.75M
5
UTHR icon
United Therapeutics
UTHR
+$2.68M

Sector Composition

Rank Sector Weight
1 Healthcare 93.75%
2 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LGND icon
26
Ligand Pharmaceuticals
LGND
$5.74B
$1.64M 1.55%
+8,200
New +$1.62M
EWTX icon
27
Edgewise Therapeutics
EWTX
$4.82B
$1.55M 1.47%
49,200
-8,800
-15% -$254K
IMTX icon
28
Immatics
IMTX
$1.29B
$1.51M 1.43%
153,750
+73,750
+92% +$723K
LXRX icon
29
Lexicon Pharmaceuticals
LXRX
$1.03B
$1.41M 1.33%
902,000
+22,000
+3% +$32K
BEAM icon
30
Beam Therapeutics
BEAM
$3.12B
$1.37M 1.3%
57,400
+7,400
+15% +$205K
ORIC icon
31
Oric Pharmaceuticals
ORIC
$1.44B
$1.3M 1.23%
102,500
-57,500
-36% -$653K
NAMS icon
32
NewAmsterdam Pharma
NAMS
$3.28B
$1.18M 1.12%
36,900
+6,900
+23% +$225K
ANNX icon
33
Annexon
ANNX
$946M
$965K 0.91%
174,250
-575,750
-77% -$3.24M
IDYA icon
34
IDEAYA Biosciences
IDYA
$4.01B
$820K 0.78%
+24,600
New +$825K
SLN
35
Silence Therapeutics
SLN
$841M
$740K 0.7%
140,500
-99,500
-41% -$548K
PTCT icon
36
PTC Therapeutics
PTCT
$6.07B
$698K 0.66%
10,250
-25,750
-72% -$1.82M
GOSS icon
37
Gossamer Bio
GOSS
$85M
$269K 0.26%
+820,000
New +$1.29M
AGIO icon
38
Agios Pharmaceuticals
AGIO
$2.03B
– –
-30,000
Closed -$817K
APLS
39
DELISTED
Apellis Pharmaceuticals
APLS
– –
-50,000
Closed -$1.26M
APOG icon
40
Apogee Enterprises
APOG
$853M
– –
-25,000
Closed -$1.89M
ARQT icon
41
Arcutis Biotherapeutics
ARQT
$3.16B
– –
-12,000
Closed -$348K
ASND icon
42
Ascendis Pharma A/S
ASND
$16.4B
– –
-5,000
Closed -$1.07M
BBIO icon
43
BridgeBio Pharma
BBIO
$15.5B
– –
-36,000
Closed -$2.75M
BCRX icon
44
BioCryst Pharmaceuticals
BCRX
$2.51B
– –
-300,000
Closed -$2.34M
BHVN icon
45
Biohaven
BHVN
$2.56B
– –
-88,000
Closed -$994K
CORT icon
46
CALL
Corcept Therapeutics
CORT
$13B
– –
-44,000
Closed -$1.53M
DNLI icon
47
Denali Therapeutics
DNLI
$3.93B
– –
-70,000
Closed -$1.16M
DNTH icon
48
Dianthus Therapeutics
DNTH
$6.2B
– –
-24,000
Closed -$989K
IMVT icon
49
Immunovant
IMVT
$9.07B
– –
-30,000
Closed -$763K
INSM icon
50
Insmed
INSM
$27.2B
– –
-10,000
Closed -$1.74M
1
2
3

Similar funds

SB
Semitam Bonam Goshen, New York $136M AUM 13.42% 1-Year Est. Return
WFA
WJ Financial Advisors Killingworth, Connecticut $136M AUM 23.45% 1-Year Est. Return
RC
Rahlfs Capital Lake Kiowa, Texas $136M AUM 33.89% 1-Year Est. Return
GBFP
Golden Bell Financial Planning Alpharetta, Georgia $136M AUM 12.99% 1-Year Est. Return
RIA
Rhodes Investment Advisors Fort Worth, Texas $136M AUM
RCWM
Red Crane Wealth Management San Francisco, California $136M AUM 18.56% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $136M AUM
HMS
Hanseatic Management Services Albuquerque, New Mexico $136M AUM

Ishara Investments's Q1 2026 Portfolio in Review

As of Q1 2026, Ishara Investments held 56 positions worth $106M, up 21% from $87.5M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Ishara Investments deployed $18.5M of net new capital in Q1 2026, opening 18 new positions and adding to 10 existing holdings. Its largest new stake was Axsome Therapeutics: 41,000 shares worth $6.93M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 96% a quarter earlier, followed by Industrials.

On the sell side, the largest reduction was Praxis Precision Medicines, an estimated $5.4M trimmed.

  • Ishara Investments's largest Q1 2026 buy was Axsome Therapeutics: 41,000 shares worth $6.93M.
  • Ishara Investments added most to Verastem in Q1 2026, an estimated $3.39M increase.
  • Ishara Investments's biggest Q1 2026 reduction was Praxis Precision Medicines, cutting an estimated $5.4M.
  • Ishara Investments fully exited Nuvation Bio in Q1 2026, selling an estimated $3.58M.
  • Ishara Investments's ten largest holdings make up 51% of its $106M portfolio in Q1 2026.
  • Ishara Investments opened 18 new positions and closed 19 in Q1 2026.
  • Ishara Investments's portfolio value rose 21% quarter-over-quarter to $106M.

Based on Ishara Investments's 13F filing for Q1 2026, filed 15 May 2026.